No Data
No Data
Tianyu Co., Ltd. (300702.SZ): It has now reached cooperation with universities to jointly carry out research related to biocatalysis
Gelonghui, May 21丨Tianyu Co., Ltd. (300702.SZ) held a performance briefing on May 21, 2024 to discuss “Is the company involved in synthetic biology?” The company replied that the company's synthetic biology technology platform is under construction, and it has now reached cooperation with universities to jointly carry out research related to biocatalysis.
Two drugs from the subsidiary of Tianyu Co., Ltd. (300702.SZ) were approved by the State Drug Administration
Tianyu Co., Ltd. (300702.SZ) issued an announcement. Zhejiang Nuode Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company (abbreviated below...
Express News | Tianyu Co., Ltd. announced that metformin vigliptin tablets (III) and compound polyethylene glycol electrolyte dispersion (III) were approved.
Tianyu Co., Ltd. (300702.SZ): Metformin vigliptin tablets (III) and compound polyethylene glycol electrolyte dispersion (III) were approved
Gelonghui Co., Ltd. (300702.SZ) announced that Zhejiang Nuode Pharmaceutical Co., Ltd. (“Nuode Pharmaceutical”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” approved and issued by the State Drug Administration for metformin vigliptin tablets (III) and compound polyethylene glycol electrolyte dispersion (III).
Tianyu Co., Ltd. (300702): Sartan's business clearly stabilized in the first quarter and is expected to enter a new round of growth cycle
Note: On April 25, the company released its 23 annual report and 24 quarterly report. Revenue of 2,527 billion yuan (-5.23%) for 23 years, net profit attributable to mother of $0.27 billion (+123.02%), net of non-return to mother
Tianyu Co., Ltd. (300702): Turned losses into rapid growth of Yingfeisartan APIs in 2023
Incident: The company released its annual report for 2023 and its quarterly report for 2014. The company achieved revenue of 2,527 billion yuan (-5.23%) in 23, net profit to mother and deducted non-net profit of RMB 27 million and RMB 63 million, to reverse losses
No Data